CIK 0000886163 · Large accelerated filer
LIGAND PHARMACEUTICALS INC
Sign in to watch- Tickers
- LGND LGNDZ LGNXZ LGNYZ LGNZZ
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 770160744
- Phone
- 858-550-7500
- Business address
- 3911 SORRENTO VALLEY BLVD, SUITE 110, SAN DIEGO, CA, 92121
- Former names
- LIGAND PHARMACEUTICALS
Securities
- LGND Common Stock Nasdaq
- LGNDZ Common stock OTC
- LGNXZ Common stock OTC
- LGNYZ Common stock OTC
- LGNZZ Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $6,585,411
- in 7 filings, $4.5M under 10b5-1 plans
Net −$6,585,411. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-09-16 | Korenberg Matthew E President & COO | Option exercise · Employee Stock Option (right to buy) | −914 | 25,949 | ||
| 2024-09-16 | Korenberg Matthew E President & COO | Option exercise · Employee Stock Option (right to buy) | −849 | 12,452 | ||
| 2024-09-16 | Korenberg Matthew E President & COO | Option exercise · Employee Stock Option (right to buy) | −3,340 | 18,500 | ||
| 2024-08-28 | Espinoza Octavio Chief Financial Officer | Option exercise | +207 | $57.22 | $12K | 23,853 |
| 2024-08-28 | Espinoza Octavio Chief Financial Officer | Option exercise | +546 | $70.04 | $38K | 24,399 |
| 2024-08-28 | Espinoza Octavio Chief Financial Officer | Option exercise · Employee Stock Option (right to buy) | −207 | 7,309 | ||
| 2024-08-28 | Espinoza Octavio Chief Financial Officer | Option exercise · Incentive Stock Option (right to buy) | −546 | 0 | ||
| 2024-08-28 | Reardon Andrew CLO & Secretary | Option exercise | +1,500 | $52.27 | $78K | 24,034 |
| 2024-08-28 | Reardon Andrew CLO & Secretary | Sale | −1,500 | $106.39 | $160K | 22,534 |
| 2024-08-28 | Reardon Andrew CLO & Secretary | Option exercise · Non-Qualified Stock Option (right to buy) | −1,500 | 61,444 | ||
| 2024-08-26 | Korenberg Matthew E President & COO | Sale | −6,177 | $105.02 | $649K | 54,722 |
| 2024-08-26 | Korenberg Matthew E President & COO | Sale | −5,212 | $106.32 | $554K | 49,510 |
| 2024-08-23 | Korenberg Matthew E President & COO | Sale | −2,037 | $104.09 | $212K | 65,174 |
| 2024-08-23 | Korenberg Matthew E President & COO | Sale | −4,275 | $105.13 | $449K | 60,899 |
| 2024-08-22 | Korenberg Matthew E President & COO | Sale | −1,157 | $105.54 | $122K | 67,211 |
| 2024-08-10 | Reardon Andrew CLO & Secretary | Shares withheld for taxes | −897 | $100.16 | $90K | 21,637 |
| 2024-08-09 | Korenberg Matthew E President & COO | Sale | −18,245 | $98.50 | $1.8M | 68,368 |
| 2024-08-08 | Davis Todd C Chief Executive Officer | Purchase | +2,500 | $97.39 | $243K | 123,010 |
| 2024-06-28 | Reardon Andrew Chief Legal Officer & | Other acquisition | +329 | $60.71 | $20K | 22,534 |
| 2024-06-28 | Korenberg Matthew E President & Chief Operating | Other acquisition | +350 | $60.71 | $21K | 86,613 |
Page 20 of 55 · 1,097 trades